| Aurobindo Pharma Limited received a “reasonable assurance” opinion on its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026, according to a report released by Sharp & Tannan Associates, Chartered Accountants. The assurance engagement, conducted in accordance with the Standard on Sustainability Assurance Engagements (SSAE) 3000, verified the company’s reported sustainability information against the BRSR Core framework and National Guidelines for Responsible Business Conduct, covering areas such as environmental impact, social responsibility, and governance practices. The Securities and Exchange Board of India (SEBI) mandates BRSR reporting for listed companies in India, and this opinion confirms Aurobindo Pharma’s adherence to the reporting criteria, though the report notes inherent limitations in sustainability reporting and restricts its use to the company’s Board of Directors. |